Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tonix Pharmaceuticals Holding (TNXP) Invested Capital (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Invested Capital data on record, last reported at $231.1 million in Q3 2025.

  • For Q3 2025, Invested Capital rose 186.26% year-over-year to $231.1 million; the TTM value through Sep 2025 reached $231.1 million, up 186.26%, while the annual FY2024 figure was $148.2 million, 27.19% up from the prior year.
  • Invested Capital reached $231.1 million in Q3 2025 per TNXP's latest filing, up from $168.0 million in the prior quarter.
  • Across five years, Invested Capital topped out at $231.1 million in Q3 2025 and bottomed at $49.3 million in Q2 2024.
  • Average Invested Capital over 3 years is $137.9 million, with a median of $140.5 million recorded in 2023.
  • Peak YoY movement for Invested Capital: crashed 64.87% in 2024, then skyrocketed 240.48% in 2025.
  • A 3-year view of Invested Capital shows it stood at $116.5 million in 2023, then increased by 27.19% to $148.2 million in 2024, then skyrocketed by 55.96% to $231.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Invested Capital were $231.1 million in Q3 2025, $168.0 million in Q2 2025, and $180.4 million in Q1 2025.